Open AccessA case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia
Author(s) -
Yang Qin,
Wang Xin
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14011
Subject(s) - medicine , rhabdomyolysis , complication , adverse effect , heart failure , erythropoiesis , anemia , surgery
Case presentation In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure. Discussion More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat. Conclusion Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.